Colorectal Surgery, Champalimaud Foundation, Lisbon, Portugal.
Colorectal Surgery, Poole Hospital NHS Trust, Poole, United Kingdom; University of Portsmouth, School of Health Sciences and Social Work, Portsmouth, United Kingdom.
Eur J Surg Oncol. 2018 Apr;44(4):484-489. doi: 10.1016/j.ejso.2018.01.088. Epub 2018 Feb 2.
In rectal cancer, increasing the interval between the end of neoadjuvant chemoradiotherapy (CRT) and surgery could improve the pathological complete response (pCR) rates, allow full-dose neoadjuvant chemotherapy, and select patients with a clinical complete response (cCR) for inclusion in a "watch & wait" program (W&W). However, controversy arises from waiting more than 8-12 weeks after CRT, as it might increase fibrosis around the total mesorectal excision (TME) plane potentially leading to technical difficulties and higher surgical morbidity. This study evaluates the type of surgical approach and short term post-operative outcomes in patients with rectal cancer that were operated before and after 12 weeks post CRT.
Patients from three centres (two in the UK, one in Portugal) who received rectal cancer surgery following neoadjuvant CRT between 2007 and 2016 were identified from prospectively maintained databases. Preoperative CRT was given to patients with high risk for local recurrence (threatened CRM ≤2 mm or T4 in staging MRI). The baseline characteristics and surgical outcomes of patients that were operated <12 weeks and ≥12 weeks after finishing CRT were analysed.
A total of 470 patients received rectal cancer surgery, of those 124 (26%) received neoadjuvant CRT. Seventy-six patients (61%) were operated ≥12 weeks after end of neoadjuvant-CRT and 48 < 12 weeks. Patients in the ≥12 weeks cohort had a higher BMI (27 vs 25, p = 0.030) and lower lymph node yield (11 vs 14, p = 0.001). The remaining of the baseline characteristics were similar between the two groups (age, operating surgeon, gender, ASA grade, T stage, surgical approach, operation). Operation time, blood loss, conversion rate, length of stay, 30-day readmission rate, 30-day reoperation rate, anastomotic leak rate, 30-day mortality, CRM clearance, and ypT0 rates were similar between the two groups. Univariate and multivariate analysis showed that delaying surgery ≥12 weeks did not affect morbidity and mortality.
In our cohort, there was no difference in short term surgical outcomes between patients operated before or after 12 weeks following CRT. The type of surgical procedures and the proposed approach did not differ due to waiting after CRT. Delaying surgery by ≥ 12 weeks is safe, feasible and does not result in higher surgical morbidity.
在直肠癌中,增加新辅助放化疗(CRT)结束与手术之间的间隔时间可以提高病理完全缓解(pCR)率,允许进行全剂量新辅助化疗,并选择临床完全缓解(cCR)的患者纳入“观察与等待”(W&W)计划。然而,等待 CRT 后超过 8-12 周会引起争议,因为这可能会导致直肠系膜全切除(TME)平面周围纤维化,从而导致技术难度增加和手术发病率升高。本研究评估了在 CRT 后 12 周之前和之后接受手术的直肠癌患者的手术方式和短期术后结局。
从 2007 年至 2016 年期间接受新辅助 CRT 后行直肠癌手术的三个中心(两个在英国,一个在葡萄牙)的前瞻性维护数据库中确定患者。对有局部复发高危因素的患者(CRM 受威胁<2mm 或 MRI 分期 T4)行术前 CRT。分析在完成 CRT 后<12 周和≥12 周进行手术的患者的基线特征和手术结局。
共 470 例患者接受了直肠癌手术,其中 124 例(26%)接受了新辅助 CRT。76 例(61%)患者在新辅助-CRT 结束后≥12 周进行手术,48 例<12 周。≥12 周组的患者 BMI 较高(27 比 25,p=0.030),淋巴结检出量较低(11 比 14,p=0.001)。两组的其他基线特征相似(年龄、手术医生、性别、ASA 分级、T 分期、手术方式、手术)。手术时间、出血量、中转率、住院时间、30 天再入院率、30 天再次手术率、吻合口漏率、30 天死亡率、CRM 切缘阴性率和 ypT0 率在两组间无差异。单因素和多因素分析表明,手术延迟≥12 周不会影响发病率和死亡率。
在我们的队列中,在 CRT 后 12 周之前或之后进行手术的患者在短期手术结局方面没有差异。由于 CRT 后等待,手术方式和拟议的手术方式没有差异。延迟手术≥12 周是安全可行的,不会导致更高的手术发病率。